Singapore, 14 March 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that members of its Executive Management team will present at the 9th Annual BioPharma Asia Convention 2016, taking place at the Suntec Singapore Convention and Exhibition Centre on 22 – 24 March 2016.
Dr. Carl Firth, Chief Executive Officer of ASLAN, will participate on the Opening Keynote Vision Panel, “Where is Asia’s biopharma industry heading in 2016 & beyond?”, at 9:10am on 22 March 2016.
Dr. Bertil Lindmark, Chief Scientific Officer, will join the keynote panel discussion, “Immuno-oncology: How far can we take it?”, at 10am on 23 March 2016. Dr. Lindmark will also present a case study on “Leveraging oriental patient pool to treat rare diseases in the West” at 3:10pm on 23 March 2016.
ASLAN has been nominated in two award categories, Pharma Executive of the Year and Asian Biotech of the Year, at the BioPharma Asia Industry Awards 2016 which coincides with the Annual BioPharma Asia Convention.
Media contacts
Emma Thompson / Stephanie Tan
Spurwing Communications Tel: +65 9107 5559
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are in phase 2: varlitinib (ASLAN001), a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com
Dr. Carl Firth, Chief Executive Officer of ASLAN, will participate on the Opening Keynote Vision Panel, “Where is Asia’s biopharma industry heading in 2016 & beyond?”, at 9:10am on 22 March 2016.
Dr. Bertil Lindmark, Chief Scientific Officer, will join the keynote panel discussion, “Immuno-oncology: How far can we take it?”, at 10am on 23 March 2016. Dr. Lindmark will also present a case study on “Leveraging oriental patient pool to treat rare diseases in the West” at 3:10pm on 23 March 2016.
ASLAN has been nominated in two award categories, Pharma Executive of the Year and Asian Biotech of the Year, at the BioPharma Asia Industry Awards 2016 which coincides with the Annual BioPharma Asia Convention.
Media contacts
Emma Thompson / Stephanie Tan
Spurwing Communications Tel: +65 9107 5559
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are in phase 2: varlitinib (ASLAN001), a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com
